Leiden, The Netherlands, 20 July 2021: Pharming announces it has entered into an exclusive lisence agreement with NewBridge Pharmaceuticals for the distribution of RUCONEST® (Conestat alfa) in the
Middle East and North Africa (MENA).

NewBridge, headquartered in Dubai, United Arab Emirates, is a regional specialty company, with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap
and partner with global pharma and biotech companies to in-license and commercialize US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved innovative therapeutics that
address unmet medical needs into MENA.

Under the terms of the agreement, NewBridge will work closely with Pharming to provide access for RUCONEST® for the treatment of acute hereditary angioedema in MENA. NewBridge will be responsible for the named patient supply and, where applicable, marketing of RUCONEST® in the region.